prevention (Jankowski and Hawk, 2006) . However, from estimates by Rothwell et al (2011) , only 20% of the latter group will derive a chemopreventive benefit from aspirin. Furthermore, the serious risks of aspirin, usually GI bleeding, are currently contentious, ranging from 0.02 to 2% per year (Jankowski and Hawk, 2006; Jankowski and Hunt, 2008; Rothwell et al, 2011) . This could mean that serious side effects from 10 years of aspirin chemoprevention would range from 0.2 to 20%. At the higher end, the benefits of chemoprevention would be nullified by the risks. The recent report from Langley et al (2011) is potentially paradigm-shifting, as it alludes to an improved risk benefit ratio for adjuvant aspirin therapy for early cancers This area has to date received relatively lesser attention compared with its chemopreventive potential. As discussed by the authors, new insights into the mechanisms of aspirin-mediated growth inhibition (such as altered endothelial cell tubule formation resulting in decreased angiogenesis) may afford unique advantages over other non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors for treating malignant tumours. Other putative effects of COX-2 on apoptosis, invasion, and immunoregulation (Ghosh et al, 2010) support targeting this enzyme in advanced, adjuvant, or neoadjuvant chemotherapy settings as well. Available observational data further suggest that aspirin use vs non-use is associated with improved survival following colorectal (Chan et al 2009) or breast cancer (Holmes et al 2010) diagnosis. However, three small randomised, controlled trials of aspirin (dose range 1000 -2400 mg per day) in combination with other anti-cancer therapies did not confirm the anticipated survival benefit. Similarly, results from the recently reported VICTOR Trial (Midgley et al 2010) , which evaluated the effects of rofecoxib (a selective COX-2 inhibitor) 20 mg per day vs placebo on overall survival among stages II and III colorectal cancer patients who had undergone potentially curative surgery and completed adjuvant chemotherapy (when indicated), also failed to demonstrate a statistically significant advantage from the active agent, although the intervention phase was terminated early (median exposure time of 7.4 months) due to concerns regarding increased cardiovascular toxicity.
Given the current evidence base, where should additional resources be invested to decipher aspirin's true anti-cancer potential? As noted by Langley et al (2011) , further investigation of the benefits and harms associated with aspirin therapy in highrisk subject cohorts (i.e., patients with newly diagnosed cancer or established premalignant conditions) may permit re-calibration of an 'acceptable' safety profile. Consideration of oncologic and nononcologic endpoints, relating to efficacy and toxicity, in all large clinical trials also seems imperative. Ideally, these disparate endpoints could be accurately measured and appropriately *Correspondence: Professor JAZ Jankowski; E-mail: janusz.jankowski@bnc.ox.ac.uk or Dr PJ Limburg; E-mail: Limburg.paul@mayo.edu weighted to more appropriately summarise the aspirin's total impact on personal and/or public health. Specific to the adjuvant therapy setting, broader use of molecular phenotyping to define tumours that are likely to be most susceptible to aspirin exposure (i.e., based on increased COX-2 expression) could improve the response rate. Finally, further attempts to clarify the genetic characteristics that differentiate aspirin responders from nonresponders may also be of merit. Several of these issues will be directly assessed by ongoing prospective studies, such as the AspECT aspirin chemoprevention trial as well as the ChOPIN genetic trial (Moayyedi and Jankowski, 2010) . It may even be possible to predict who will get a response to aspirin, based upon their genome.
In summary, the case for aspirin therapy continues to get stronger. It may never be too late for aspirin adjuvant therapy, even if chemoprevention is not feasible. However, more well-designed randomised controlled trials are needed with adequate follow-up time before definitive clinical recommendations can be given.
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